Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "FDA"


25 mentions found


CNBC's Jim Cramer on Tuesday explained why he continues to be bullish about pharmaceutical giant Eli Lilly . Continually confident about Eli Lilly because of the enormous success of its weight loss and diabetes drugs, he said the company's new Alzheimer's treatment has the potential to further boost business. On Monday, a panel of advisors to the Food and Drug Administration unanimously recommended Eli Lilly's Alzheimer's drug, currently known as donanemab. "I think this advisory committee decision on their Alzheimer's drug does precisely that." Eli Lilly did not immediately respond to request for comment.
Persons: CNBC's Jim Cramer, Eli Lilly, Eli Lilly's, it's, Cramer, they've Organizations: Food and Drug Administration, FDA Locations: U.S, Biogen
Eli Lilly — Eli Lilly shares rose 2% after a panel of FDA advisors recommended the approval of its Alzheimer's drug known as donanemab. General Motors — The automaker's stock added more than 1% after its board authorized a $6 billion stock buyback program . Shopify — The e-commerce stock rose about 1% after JPMorgan initiated coverage with an overweight rating. Apple — Apple shares slipped less than 1% a day after the iPhone maker's Worldwide Developers Conference, where it revealed its artificial intelligence plans , called Apple Intelligence. GameStop — GameStop shares slipped 1% before the bell, continuing its volatile ride.
Persons: Eli Lilly, General Motors, Siri, Keith Gill's, Lee Cole, , Jesse Pound, Sarah Min Organizations: General, JPMorgan, Apple, Apple Intelligence, Technology, Reuters, Apollo, Kyndryl Holdings, GameStop, Calavo, , Calavo Growers
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailJim Cramer looks at Eli Lilly's outlook as the company's Alzheimer drug goes through FDA'Mad Money' host Jim Cramer breaks down Eli Lilly's success in pharmaceutical drugs and where the stock can go from here.
Persons: Jim Cramer, Eli Lilly's Organizations: FDA
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Financials, Morgan Stanley, Wells, , Jim, Eli Lilly, Biogen, Jim Cramer's, LLY, DOV Organizations: CNBC, Federal, GE Healthcare, FDA, GE, JPMorgan, Dover Locations: That's, Dover
Eli Lilly became the most valuable health-care company in the world on the back of its blockbuster diabetes and obesity drugs. The billions of dollars in Eli Lilly is investing in manufacturing capacity support the idea that the long-term opportunity is immense. Adding Eli Lilly to the market could help address some of the obstacles that limited Leqembi's sales early on. Eli Lilly, which has spent billions in search of a successful Alzheimer's treatment , had hoped for donanemab to be approved by now. A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana.
Persons: Eli Lilly, donanemab, Eli Lilly's, Donanemab, Leqembi —, Biogen, , Jim Cramer's, Ken Langone, Morgan Stanley, Cantor Fitzgerald, Leqembi, Jim Cramer, Jim, Scott Olson Organizations: Food and Drug Administration, FactSet, Novo Nordisk, FDA, GE Healthcare, CNBC, Company, Getty Locations: GLP, Indianapolis , Indiana
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. "Notice where Stanley Black & Decker is when you have a good day for the bonds," Jim Cramer pointed out. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, you'll, Stanley Black, Decker, Dupont, Ed Breen, Jim, Eli Lilly, Eli Lilly Alzheimer's, Banks, Wells, Michael Santomassimo, Santomassimo, Morgan Chittum, We've, Tom Jorden, Coterra, Jorden, Jerome Powell, Jim Cramer's Organizations: CNBC, Longtime, Apple, Treasury, Club, DuPont, GE Healthcare, Huntington, Investing Club, Coterra Energy, Broadcom, VMware, Jim Cramer's Charitable
FDA advisers say Eli Lilly's Alzheimer's treatment is effective
  + stars: | 2024-06-10 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA advisers say Eli Lilly's Alzheimer's treatment is effectiveCNBC's Angelica Peebles joins 'Closing Bell' to discuss the FDA's advisers vote on Eli Lilly's Alzheimer's drug.
Persons: Eli Lilly's, Angelica Peebles
Abbott Laboratories announced Monday it received approval from the U.S. Food and Drug Administration for two new continuous glucose monitoring systems, including one for people who don't have diabetes. A continuous glucose monitor, or a CGM, is a small sensor that pokes through the skin and tracks a person's glucose levels in real time. One of Abbott's new systems, Libre Rio, is for patients with Type 2 diabetes who do not take insulin. Oftentimes, users need a valid CGM prescription to participate in these programs, so Abbott's new over-the-counter offering could be more accessible for some consumers. Abbott competitor Dexcom , which also sells CGM systems, received FDA approval for its first-ever over-the-counter CGM in March.
Persons: Robert B, Ford, Abbott, Abbot, Lingo, Dexcom Organizations: Abbott Laboratories, U.S . Food, Drug Administration, Libre Locations: Vegas, Las Vegas , Nevada, U.S, Libre Rio
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly's Alzheimer drug is 'a nice additional therapy', says Mizuho's Jared HolzJared Holz, Mizuho Securities healthcare equity strategist, joins 'Squawk Box' to discuss the FDA's review of Eli Lilly's experimental Alzheimer drug, whether the drug is a game changer, and more.
Persons: Eli, Jared Holz Jared Holz, Eli Lilly's Organizations: Mizuho Securities Locations: Mizuho
FDA advisers say Eli Lilly Alzheimer's treatment is effective
  + stars: | 2024-06-10 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA advisers say Eli Lilly Alzheimer's treatment is effectiveDr. Scott Gottlieb, Former FDA Commissioner, joins 'Closing Bell Overtime' to talk news that the FDA has deemed Eli Lilly's Alzheimers treatment as effective.
Persons: Eli Lilly Alzheimer's, Scott Gottlieb, Eli Lilly's Organizations: FDA
CNN —The US Food and Drug Administration is warning consumers and retailers to not “eat, sell or serve” any of Diamond Shruumz-brand’s microdosing chocolate bars after people across four states were left hospitalized. Eight people reported falling ill after eating Diamond Shruumz’s chocolates, the FDA said in an advisory. People who consumed the chocolate bars reported experiencing symptoms that include “seizures, central nervous system depression (loss of consciousness, confusion, sleepiness), agitation, abnormal heart rates, hyper and hypotension, nausea and vomiting,” said the FDA. CNN has reached out to Diamond Shruumz for comment but has not heard back by the time of publishing. If you or someone you know becomes ill after consuming Diamond Shruumz’s chocolate bars, the FDA recommends speaking to a health care provider and/or contacting the Poison Help Line at 1-800-222-1222.
Persons: Diamond, , Dr, Sanjay Gupta, Diamond Shruumz Organizations: CNN, Food and Drug Administration, FDA, People, CNN Health, US Centers for Disease Control, Centers Locations: Arizona, Indiana, Nevada, Pennsylvania
Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. A panel of independent advisors to the Food and Drug Administration on Monday recommended Eli Lilly 's Alzheimer's drug donanemab, paving the way for the treatment to receive full approval in the U.S. later this year. If cleared for use, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the U.S. market after another treatment called Leqembi from Biogen and its Japanese partner Eisai. In a second vote, advisors unanimously said the benefits of Eli Lilly's donanemab outweigh its risks. It was another blow to Eli Lilly, which initially expected donanameb to win approval at the end of last year.
Persons: Eli Lilly, Eli Lilly's donanemab, Eisai, Eli Lilly's, Sarah Dolan, Dolan, Mark Mintun, donanameb, Leerink, David Risinger, Risinger Organizations: Food and Drug Administration, FDA Locations: Indianapolis , Indiana, U.S, Biogen, Black
CNN —There could be a combined Covid-19 and flu shot in our future, although it won’t be ready for this year’s flu season. On Monday, vaccine maker Moderna announced positive late-stage trial results for its Covid/flu combination vaccine it calls mRNA-1083. Other companies have been testing a combined Covid-flu vaccine, but Moderna is the first to announce positive late-stage trial results. The trial studied the vaccine in two different age groups with about 4,000 adults in each age category. Few people got the latest Covid shot, studies show.
Persons: , Francesca Ceddia, ” Ceddia, Covid, Spikevax, Moderna, Sue Peschin, Dr, Sanjay Gupta, Peschin, ” Peschin, Organizations: CNN, Moderna, Public, US Centers for Disease Control, Food, Covid, FDA, Alliance for Aging Research, CNN Health, CDC Locations: United States
The FDA is investigating Diamond Shruumz-brand microdosing chocolate bars. Eight people fell ill after consuming the product, the agency said. Sign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . AdvertisementEight people in four states fell ill after consuming Diamond Shruumz-brand microdosing chocolate bars, the FDA said on Friday.
Persons: Diamond, , Microdosing, It's, they've Organizations: FDA, Service, Business Locations: Silicon Valley
But the virus can also cause severe illness in adults 50 and up — or even younger — with underlying chronic conditions such as asthma, diabetes and congestive heart failure. GSK's shot won't reach that new patient population just yet. Safety data in adults ages 50 to 59 was also consistent with data in adults 60 and above, according to GSK. Regulatory agencies in Europe, Japan and other areas are currently reviewing GSK's application to expand Arexvy's approval to high-risk adults ages 50 to 59. GSK's shot is approved in nearly 50 countries, a spokesperson for the company told CNBC.
Persons: Phil Dormitzer, Dormitzer, Luke Miels, Arexvy, GSK's Organizations: Drug Administration, GSK, FDA, Centers for Disease Control, CNBC, CDC, Pfizer, Moderna, U.S Locations: British, Europe, Japan
Jim Cramer's week ahead: Fed meeting and CPI report
  + stars: | 2024-06-07 | by ( Julie Coleman | ) www.cnbc.com   time to read: +2 min
CNBC's Jim Cramer on Friday guided investors through next week's most market-moving events, highlighting the Federal Reserve's meeting and the latest consumer price index report. Nvidia will implement its 10-for-1 stock split, and Cramer said shares might drop on Monday as buyers take profits. Oracle reports on Tuesday, and Cramer said he's not sure how this enterprise software company will fare. Casey's General Stores will also report that day, and Cramer said business is strong and the stock has been "a total winner." In that vein, the Fed will likely leave rates higher for longer at its Wednesday meeting, Cramer said.
Persons: CNBC's Jim Cramer, Jay Powell, Eli Lilly, Cramer, Eli Lilly's, he's, hasn't, nonfarm, He'll Organizations: Nvidia, Apple, Apple's, Conference, Vision Pro, FDA, Oracle, Casey's, Broadcom, Signet, Adobe Locations: Figma
Market wrap : Stocks were mixed and drifting in Friday afternoon trading. Wall Street's earlier gains Friday came despite a surge in bond yields and another pushout of Federal Reserve interest rate cut odds. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Morgan Stanley, Friday's, Eli Lilly, Lilly, Jim Cramer's, Jim Organizations: CNBC, Nasdaq, Abbott Laboratories, Nvidia, Apple, Developers, FDA, Broadcom, Jim Cramer's Charitable Locations: Wells
Alphabet announced on Wednesday that Eli Lilly Chief Financial Officer Anat Ashkenazi will be its new CFO after an almost year-long search. Shares of Eli Lilly have soared 90% in the past year and are trading at a record. When she joined Eli Lilly in 2001, she came in through the company's new venture capital division, which was co-founded by her then-spouse Ron Laufer. Fastest growth in decadesFounded in 1876, Eli Lilly has long been one of the major U.S. pharmaceutical companies. But the last couple years have marked a period of historic growth for Eli Lilly due to the exploding popularity of GLP-1s.
Persons: Anat Ashkenazi, Eli Lilly Eli Lilly Alphabet's, Ruth Porat, Eli Lilly, Ashkenazi, it's, Eli Lilly's, David Ricks, Morgan Stanley, Sundar Pichai, Hollie Adams, Ron Laufer, John Smiley, Eli, It's, Trump, Eli Lilly's Covid, we're, Askhenazi, OpenAI's, Larry Page, Sergey Brin, CNBC's Eric Rosenbaum, Toby Lyles Organizations: San, San Francisco Bay Area, Google, Economic, Bloomberg, Getty, CNBC, Tel Aviv University, Hebrew University, U.S . Food, Drug, U.S . Department of Justice, FDA, Reuters, Employees, NBC Locations: U.S, Indiana, San Francisco Bay, Davos, Switzerland, Israel, biopharma, North Carolina, Germany, New Jersey
The FDA reverses its ban on Juul e-cigarettes
  + stars: | 2024-06-06 | by ( Rob Wile | ) www.cnbc.com   time to read: +1 min
The Food and Drug Administration announced Thursday that it has reversed its ban on Juul e-cigarettes while it reviews new court decisions and considers updated information provided by the vape-maker. The FDA first stopped the company from marketing its products in 2022, but they have stayed on shelves pending an appeal. Even as Juul has pursued its appeal of the 2022 marketing ban, that initial FDA ruling significantly disrupted the company's finances, prompting a bailout from two of its largest investors, The Wall Street Journal has reported. Juul also continues to face lawsuits from consumers saying its products harmed their health. To date, the FDA has given only 23 e-cigarette products, made by just three companies, official approval to be marketed to consumers.
Persons: Juul Organizations: Drug Administration, FDA Locations: Flatbush, Brooklyn, New York City, U.S
CNN —After decades of false starts, researchers say they are finally making progress on a long-acting and reversible birth control option for men. The gel was developed by the National Institutes of Health and the nonprofit Population Council, and it takes much the same approach as birth control pills for women. “I would say our expectation was that it would be similar to hormonal birth control pills. The gel also seems to have other advantages over female birth control. To him, it doesn’t feel fair that his partner has to shoulder the burden of birth control.
Persons: “ We’ve, , Diana Blithe, Blithe, , that’s, Matthew Treviño, it’s, he’s, “ I’ve, Emily Fletcher, , Roe, Wade, ’ “ Fletcher, Treviño, ” Treviño, That’s, Christina Wang, Dr, Sanjay Gupta, Wang, they’ll, Brian Nguyen Organizations: CNN, National Institutes of Health, Population Council, NIH’s National Institute of Child Health, Human, Endocrine Society, World Health Organization, University of California, UC Davis, US Food and Drug Administration, Lundquist, Medical, Get CNN, CNN Health, University of Southern Locations: Boston, Sacramento , California, Davis, University of Southern California
Meta 's chief artificial intelligence scientist Yann LeCun has spent much of the past week sparring with Elon Musk over the Tesla CEO's treatment of scientists and news organizations, and for spreading false conspiracies on social media. The spat began days earlier, on May 27, after Musk took to X to encourage people to apply for roles at his AI startup, xAI. Musk, who has previously called for the prosecution of Fauci, posted on X, "Why do Dems love Fauci so much." Musk said in a post on X Monday that LeCun has been "out of touch with AI for a long time." "I'm sure the scientists who hide behind this collective name are super happy about that," LeCun said on X.
Persons: Yann LeCun, Elon Musk, LeCun, Musk, Anthony Fauci, Fauci, Mark Zuckerberg, Bill Gates, Investor Mark Cuban, Dustin Moskovitz, Musk's, Tesla, hasn't, He's Organizations: Elon, Google, Microsoft, Meta, Investor, Diversity, Equity, LeCun, Medical Internet Research, Trump Locations: xAI
A Mississippi restaurant pleaded guilty to misbranding its fish. It mislabeled species, and advertised imported fish as local. download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . You can opt-out at any time by visiting our Preferences page or by clicking "unsubscribe" at the bottom of the email. AdvertisementAn iconic Mississippi restaurant pled guilty to misbranding the species of seafood on its menu, according to the Justice Department, and passing off imported fish as locally caught.
Persons: , Mary Mahoney's Organizations: FDA, Service, Justice Department, US, Office, Southern District of, Business Locations: Mississippi, Biloxi, Southern District, Southern District of Mississippi
Two years later, abortion rights remain a major issue in the 2024 election. Vice President Kamala Harris has taken the lead in the Biden campaign's push to highlight abortion rights on the campaign trail. The Senate filibuster requires a de facto 60-vote majority for legislation that would enshrine nationwide abortion rights protection into law. AdvertisementSome legal experts have also questioned whether Congress has the power to guarantee abortion access. Project 2025, an unofficial partnership of right-wing think tanks, has outlined an ambitious series of plans to curtail abortion rights if Trump wins in November.
Persons: , Roe, Wade, Joe Biden's, Biden, Donald Trump, There's, Trump, Here's, Kamala Harris, Saul Loeb, Joe Biden, It's, reimbursing, Mark Wilson, Arizona, Katie Hobbs, hasn't Organizations: Service, Business, CBS, New York Times, Trump, Biden, Getty, Senate, GOP, Supreme, Pentagon, Republican, Justice Department, Republicans, Gov Locations: Arizona, Arizonans, Siena, mifepristone, Florida
Moderna and Merck released more positive three-year data Monday on their experimental vaccine, given to patients with the most deadly form of skin cancer in combination with the therapy Keytruda. The vaccine together with Merck's Keytruda improved survival and showed long-lasting efficacy in a midstage study in patients with a deadly form of skin cancer. Melanoma is responsible for the large majority of skin cancer deaths, according to the American Cancer Society. Moderna is also conducting another phase three trial of the vaccine in patients with a type of lung cancer. This year, Merck and Moderna started a two-part mid- to late-stage trial on the vaccine and Keytruda in patients at an advanced stage of a common skin cancer.
Persons: Merck's, Kyle Holen, Keytruda, Stephane Bancel, Bancel Organizations: Moderna, Merck, American Society of Clinical Oncology, CNBC, U.S . Food, Drug Administration, FDA, American Cancer Society Locations: Chicago, U.S, Moderna
The anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs said. New products such as Eli Lilly's Zepbound prompted the bank to raise its forecast. download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . AdvertisementThe market for weight-loss drugs such as Ozempic and Wegovy will keep surging due to new products including Eli Lilly's Zepbound, according to Goldman Sachs. In a research note the bank forecast that the sector will be worth $130 billion by 2030 — $30 billion higher than its previous projection.
Persons: Goldman Sachs, Eli Lilly's Zepbound, , Wegovy, Eli Lilly, Chris Shibutani Organizations: FDA, pharma, Service, Nordisk, Business Locations: Danish
Total: 25